Physician profile
Ronald Charles
NPI 1386964674
$1,014.81
in general payments reported to CMS, 2019-2025
12 companies · $384 in 2025
The $384 reported for 2025 was more than what 87% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $153 · 2023: $155 · 2024: $324 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $556.48 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $93.71 | 2024-2025 | |
| Boston Scientific Corporation | $82.61 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.07 | 2022 | |
| Abbvie INC. | $49.03 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.88 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $26.97 | 2023-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.64 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $22.23 | 2025 | Zerbaxa |
| Novo Nordisk INC | $19.30 | 2023 | Rybelsus, Ozempic |
| Amgen INC. | $17.11 | 2024 | Repatha |
| Electromed, INC. | $13.78 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.